NCT04351386

Brief Summary

The proposed clinical study aims to validate the diagnostic performance, compared to a reference ECG, of the ECG-SW1 software and the PPG-SW1 software integrated into the HWA09 watch developed by Withings for the automatic identification of atrial fibrillation (AF).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
283

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2019

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 20, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 8, 2020

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 17, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 7, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 7, 2021

Completed
Last Updated

November 16, 2021

Status Verified

November 1, 2021

Enrollment Period

1.3 years

First QC Date

April 8, 2020

Last Update Submit

November 15, 2021

Conditions

Keywords

Atrial FibrillationArrythmia, CardiacCardiovascular DiseaseHeart DiseaseWearable Electronic DeviceWatchElectrocardiographyECGPhotoplethysmographyPPG

Outcome Measures

Primary Outcomes (2)

  • Sensitivity of the automatic classification in AF by ECG-SW1 of HWA09 single-lead ECG against reference 12-lead ECG

    sensitivity from the 2x2 confusion matrix AF vs 'non-AF'

    1 year

  • Sensitivity of the automatic classification in NSR by ECG-SW1 of HWA09 single-lead ECG against reference 12-lead ECG

    sensitivity from the 2x2 confusion matrix NSR vs 'non-NSR'

    1 year

Secondary Outcomes (12)

  • Sensitivity of the automatic classification in AF by PPG-SW1 of the HWA09 PPG against reference 12-lead ECG

    1 year

  • Sensitivity of the automatic classification in NSR by PPG-SW1 of the HWA09 PPG against reference 12-lead ECG

    1 year

  • Sensitivity of the cardiologists' classification in AF from the HWA09 ECG

    1 year

  • Sensitivity of the cardiologists' classification in SR from the HWA09 ECG

    1 year

  • Accuracy of the visibility of P-waves of single-lead ECG from HWA09

    1 year

  • +7 more secondary outcomes

Study Arms (3)

Atrial Fibrillation (AF)

Patients diagnosed with AF during reference ECG

Device: AF Detection

Normal Sinus Rhythm (NSR)

Patients with NSR during reference ECG

Device: AF Detection

Other Arrythmia

Patients diagnosed with an arrhythmia other than AF during the reference ECG

Device: AF Detection

Interventions

Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG

Atrial Fibrillation (AF)Normal Sinus Rhythm (NSR)Other Arrythmia

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Every eligible patient doing a medical examination at the investigation center will be asked to take part in the study.

You may qualify if:

  • Individuals over 18yo
  • Individuals who expressed their non-opposition to take part in the study
  • Individuals affiliated to a social security system or eligible

You may not qualify if:

  • Vulnerable individuals according to the regulation in force :
  • Pregnant, parturient or breastfeeding women
  • Individuals deprived of liberty by a court, medical or administrative order
  • Individuals under 18yo
  • Individuals legally protected or unable to express their non-opposition to take part in
  • Individuals unaffiliated to or not beneficiary of a social security system
  • Individuals who fit in multiple categories above
  • Individuals having refused to take part in the study
  • Individuals linguistically or mentally unable to express their non-opposition
  • Individuals physically unable to wear a watch
  • Individuals with an electrical pacing by a pacemaker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Institut Cœur Paris Centre Turin

Paris, Île-de-France Region, 75008, France

Location

Hopital Europeen Georges Pompidou

Paris, Île-de-France Region, 75015, France

Location

Centre Cardiologique du Nord

Saint-Denis, Île-de-France Region, 93200, France

Location

Related Publications (1)

  • Campo D, Elie V, de Gallard T, Bartet P, Morichau-Beauchant T, Genain N, Fayol A, Fouassier D, Pasteur-Rousseau A, Puymirat E, Nahum J. Atrial Fibrillation Detection With an Analog Smartwatch: Prospective Clinical Study and Algorithm Validation. JMIR Form Res. 2022 Nov 4;6(11):e37280. doi: 10.2196/37280.

MeSH Terms

Conditions

Atrial FibrillationArrhythmias, CardiacCardiovascular DiseasesHeart Diseases

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • David CAMPO

    Withings

    STUDY DIRECTOR
  • Julien NAHUM

    Centre Cardiologique du Nord

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 8, 2020

First Posted

April 17, 2020

Study Start

December 20, 2019

Primary Completion

April 7, 2021

Study Completion

April 7, 2021

Last Updated

November 16, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will not share

Individual patient data (IPD) are considered as confidential in this study. After the end the final quality control, the database will be frozen and all the IPD will be archived .

Locations